礼来表示，患者每四周静脉输注一次Kisunla，每瓶售价为695.65美元，6个月疗程的费用为12,522美元，12个月疗程的费用为32,000美元，18个月疗程的费用为 ...

日本是donanemab获得批准的第二个主要市场，该药物此前已在美国以Kisunla的品牌名称上市。 第14名谷歌A类股（GOOGL）收高0.75%，成交32.74亿美元。

Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive ...

The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly ...

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive impairment ...

新京报讯（记者张兆慧）近日，欧洲药品管理局的药品委员会表示，对卫材和渤健的阿尔茨海默病药物仑卡奈单抗的上市许可 ...

(Reuters) - Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment option after Eisai and Biogen's ...